BioCryst Pharmaceuticals
BCRX
112 hedge funds and large institutions have $370M invested in BioCryst Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 9 closing their positions.
214% more call options, than puts
Call options by funds: $25.2M | Put options by funds: $8.02M
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
79.16% more ownership
Funds ownership: 0% → 79.16% (+79%)
49% more capital invested
Capital invested by funds: $248M → $370M (+$122M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
9% more funds holding
Funds holding: 103 → 112 (+9)
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$6.92M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.87M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.59M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.95M |
| 5 |
VMI
VHCP Management II
New York
|
+$1.82M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$6.06M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$3.38M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.1M |
| 4 |
PC
Paulson & Co
New York
|
-$1.62M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.02M |
BCRX Hedge Fund Activity: Q4 2016 in Review
112 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2016, worth a combined $370M — up 49% from $248M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BCRX positions and 9 closed out — a net gain of 10 holders — while 37 added to existing stakes and 28 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $6.92M. The largest seller was Deerfield Management, cutting an estimated $6.06M.
- 112 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2016, up from 103 in Q3 2016.
- Funds reported $370M of BioCryst Pharmaceuticals stock for Q4 2016, up 49% quarter-over-quarter.
- 19 funds opened new BioCryst Pharmaceuticals positions in Q4 2016 and 9 closed out, a net change of +10 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2016 was Perceptive Advisors, an estimated $6.92M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2016 was Deerfield Management, an estimated $6.06M sold.
Based on aggregated 13F filings for Q4 2016.